{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T02:44:45Z","timestamp":1772246685925,"version":"3.50.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016255","name":"INOVIO Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016255","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000943","name":"Commonwealth Scientific and Industrial Research Organisation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000943","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    The ongoing COVID-19 pandemic has resulted in significant global morbidity and mortality on a scale similar to the influenza pandemic of 1918. Over the course of the last few months, a number of SARS-CoV-2 variants have been identified against which vaccine-induced immune responses may be less effective. These \u201cvariants-of-concern\u201d have garnered significant attention in the media, with discussion around their impact on the future of the pandemic and the ability of leading COVID-19 vaccines to protect against them effectively. To address concerns about emerging SARS-CoV-2 variants affecting vaccine-induced immunity, we investigated the neutralisation of representative \u2018G614\u2019, \u2018501Y.V1\u2019 and \u2018501Y.V2\u2019 virus isolates using sera from ferrets that had received prime-boost doses of the DNA vaccine, INO-4800. Neutralisation titres against G614 and 501Y.V1 were comparable, but titres against the 501Y.V2 variant were approximately 4-fold lower, similar to results reported with other nucleic acid vaccines and supported by\n                    <jats:italic>in silico<\/jats:italic>\n                    biomolecular modelling. The results confirm that the vaccine-induced neutralising antibodies generated by INO-4800 remain effective against current variants-of-concern, albeit with lower neutralisation titres against 501Y.V2 similar to other leading nucleic acid-based vaccines.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2021.694857","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T10:00:26Z","timestamp":1624615226000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets"],"prefix":"10.3389","volume":"12","author":[{"given":"Shane","family":"Riddell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Goldie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander J.","family":"McAuley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Kuiper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Durr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim R.","family":"Blasdell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Tachedjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian D.","family":"Druce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor R. F.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate E.","family":"Broderick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seshadri S.","family":"Vasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking Changes in SARS-CoV-2 Spike: Evidence That D614G Increases Infectivity of the COVID-19 Virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41467-020-20247-4","article-title":"Neutralizing Antibody Titres in SARS-CoV-2 Infections","volume":"12","author":"Lau","year":"2021","journal-title":"Nat Commun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00442-6","article-title":"Immune Correlates of SARS-CoV-2 Protection","volume":"20","author":"Brown","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMc2100362","article-title":"New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications","volume":"384","author":"Abdool Karim","year":"2021","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41591-021-01285-x","article-title":"Sars-CoV-2 501y.V2 Escapes Neutralization by South African COVID-19 Donor Plasma","volume":"27","author":"Wibmer","year":"2021","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41586-021-03471-w","article-title":"Escape of SARS-CoV-2 501y.V2 From Neutralization by Convalescent Plasma","volume":"593","author":"Cele","year":"2021","journal-title":"Nature"},{"key":"B8","unstructured":"The COVID-19 Candidate Vaccine Landscape and Tracker2021"},{"key":"B9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41541-020-00246-8","article-title":"Experimental and in Silico Evidence Suggests Vaccines Are Unlikely to be Affected by D614G Mutation in SARS-CoV-2 Spike Protein","volume":"5","author":"McAuley","year":"2020","journal-title":"NPJ Vaccines"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/s41467-020-16505-0","article-title":"Immunogenicity of a DNA Vaccine Candidate for COVID-19","volume":"11","author":"Smith","year":"2020","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.07.21256652","article-title":"Safety and Immunogenicity of INO-4800 DNA Vaccine Against SARS-CoV-2: A Preliminary Report of a Randomized, Blinded, Placebo-Controlled, Phase 2 Clinical Trial in Adults at High Risk of Viral Exposure","author":"Mammen","year":"2021","journal-title":"medRxiv"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.20289","article-title":"Scalable Molecular Dynamics With NAMD","volume":"26","author":"Phillips","year":"2005","journal-title":"J Comput Chem"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: Visual Molecular Dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J Mol Graphics"},{"key":"B15","volume-title":"Nanome: Creating Powerful, Collaborative and Scientific Vr Tools","year":"2020"},{"key":"B16","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1126\/science.185.4154.862","article-title":"Amino Acid Difference Formula to Help Explain Protein Evolution","volume":"185","author":"Grantham","year":"1974","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","article-title":"Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding","volume":"182","author":"Starr","year":"2020","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.14.431117","article-title":"Mutation N501Y in RBD of Spike Protein Strengthens the Interaction Between COVID-19 and Its Receptor Ace2","author":"Tian","year":"2021","journal-title":"bioRxiv"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1101\/2020.12.31.425021","article-title":"Comprehensive Mapping of Mutations in the SARS-CoV-2 Receptor-Binding Domain That Affect Recognition by Polyclonal Human Plasma Antibodies","volume":"29","author":"Greaney","year":"2021","journal-title":"Cell Host Microbe"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 Variants Escape Neutralization by Vaccine-Induced Humoral Immunity","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1101\/2021.04.14.439719","article-title":"Ino-4800 DNA Vaccine Induces Neutralizing Antibodies and T Cell Activity Against Global SARS-CoV-2 Variants","author":"Andrade","year":"2021","journal-title":"bioRxiv"},{"key":"B22","unstructured":"Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern2021"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.694857\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T10:00:31Z","timestamp":1624615231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.694857\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2021.694857"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.694857","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.04.17.440246","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]},"article-number":"694857"}}